Senti, 5-ALA may of course had played a role in increasing survival but in that case it would be most effective already during the first or second year on trial. However, up to March 2017, when the average stay on trial for the last 108 patients was approximately 22 months, the rate of survival was not remarkable because by that time already 46 of the 108 patients (42.6%) had died.
Instead, for that group of 108, we see the greatest survival benefit occurring post 22 months on trial. This delayed benefit suggests that immunological memory is in play and that suggests to me DCVax-L. Witness that in the last group of 108 patients, at least 42 of the 62 patients who already survived an average of 22 months, became post 36 months survivors.
So 5-ALA may have had an early positive survival effect but I tend to think that DCVax-L had an even more positive but later survival role.
Market Data 
Markets 
AI
